Separate names with a comma.
Discussion in 'Novartis' started by Ringling Brother, Apr 10, 2012 at 9:50 AM.
Step right up folks place your bets
Done deal - $4 co-pay for diovan and exforge - exforge finshed
Reclast patent done = no more reclast
Fanapt contract done at end of year AND no managed care contracts = NO MORE Fanapt
ALL EQUALS No more Primary Care AND No more Neuro-Psych division
Both will be merged with 1 less product on each side
Dec 12 or Jan 13 minus the old severance = Novartis down the drain
At least 400 more down-sized
TIME to get OUT
You people are a bunch of morons. How much smaller do you think this company can get? Arcapta was launched two weeks ago in specialty, this will be in general medicines bag Jan 1. In case you didn't read the data released last week this is a blockbuster product in a huge market. This gets you through 2013 then new product launches start in 2014.
This product is a dog! The entire market is short acting and we launch long acting in a generic marketplace! Also no real clinical advantages with the dose we have approved! Go drink more kool-aid if you really think this product is a winner!
Dec 21012..Reclast goes generic just after this and we will only have patch in a declining ALZ market
Funny. Products in 2014. What was the tag line:
Place to be.
Robust pipeline (actually robust pipedream).
Whatever happend to Galvus? Wasn't that supposed to be a sleeping blockbuster?
What about Ilaris? The next best thing since the advent of them there ginsu knives. Cut through steel, still sharp as ever.
Lotrel with the "rock soldi" patent protection through 2017, and these s was back in 2007.
Nofatus: a ship of fools.
Be bitter now I understand. You will all be reapplying in two years when you realize how good you had it. Severance will run out and job market is shrinking. I guess time will tell but I don't see one of the largest drug companies closing up shop.
But the available jobs will be in China and Brazil not in the US
So glad I don't have to work.
It’s not about closing shop. Its about innovating more effective, less costly, better controls on delivering product message and getting samples to MDs.
We drug reps are a unrealistic and naive if we think that technology wont drastically reduce the need for reps
Listen I am sorry you are no longer here, however just because you were let go doesn't mean this company is sinking. The industry is changing we all know this but they will always need some reps to some capacity. I would rather be at Novartis then any other company. You are free to post your opinion I am just posting mine. Personally I think this will be a better place to work going forward. There were way to many of us here. It is unfortunate this happened but this is the world we live in and if you stay in this industry it will be the same at any other company. Bottom line is you need to produce, the days of hiding in the weeds are over.
I was with William H. Rorer Pharmaceuticals back in 1982 and 1983. We had 350 reps nationwide and did fine. Each rep called on hospitals (including hospital pharmacy), private practice primary care and specialist physicians, retail pharmacies, pharmacy chain accounts and drug wholesalers. We did this on a 6 week rotation. The only rep overlap was if a doctor had multiple offices with offices happening to be in two territories.
We had multiple products that we promoted including:
Slo-Bid, Slo-Phyllin (both theophyllines), Maalox, Maalox T/C, Maalox Plus, Ascriptin, Ascriptin A/D, Parapectolin and Emetrol. Maybe one or two more, but the names escape me right now. This was before managed care and we did just fine with 350 reps, all the accounts we covered and the products we had. It was nice to keep busy and there was little/no time to goof off. So given the current marketplace and the products that Novartis is projected to be promoting a year from now, 400 is maybe still a bit rep heavy.
Given changes in the severance plan, the "Golden Ticket", if you want to call it that, looks a bit tarnished. Anyone left today should seriously look to get out as soon as possible because of that and all the additional grief they will be putting you through.
You must be right why else would HR announce a new reduced severance package days after laying off 2000 people
Must be all those pending blockbusters LMAO !!! Yuk Yuk Yuk !
Good luck finding a well paying job with another pharmacetical company where you will be the low man on the pole. If you think the grass is greener at other pharma companies you are in for a real surprise. Every company is going though the same thing. If you can get in with device or biologic company that is your best bet. Otherwise why would you not ride this out?? At least Novartis has a pipeline of potential products that they are attempting to bring to market. What are you going to go work for Sankyo or GSK and claim that it is so much better? Keep dreaming.